早期与晚期乳腺癌间低HER2表达的演变
本研究回顾了2014年1月至2020年12月期间232例HER2阴性乳腺癌患者数据,按HER2免疫组化表达分为HER2-zero(IHC 0)和HER2-low(IHC 1+或2+/ISH阴性)亚组,评估原发肿瘤与晚期首次活检之间HER2表达的演变。结果显示原发肿瘤与配对活检间HER2表达存在不一致(K=0.33,95%CI 0.21-0.44),44%的HER2-zero原发肿瘤活检时HER2评分升高,22%的HER2-low原发肿瘤转为HER2-IHC 0;HER2-low与HER2-zero原发肿瘤间生存结局无差异。
要点
- 原发肿瘤与晚期活检间HER2表达存在不一致(K=0.33,95%CI 0.21-0.44)。
- 44%的HER2-zero原发肿瘤在活检时HER2评分升高,22%的HER2-low转为HER2-IHC 0。
- HER2-low与HER2-zero原发肿瘤间无生存差异。
核心结论
- HER2-low表达在乳腺癌中是动态的,可能在晚期阶段富集,但未证实HER2-low表达具有预后意义。
研究设计与样本
- 回顾性分析2014年1月至2020年12月期间转诊的232例符合最新ASCO/CAP指南的HER2阴性乳腺癌患者数据。
主要发现
- 总体人群中,原发肿瘤与配对活检间HER2表达存在不一致(K=0.33,95%CI 0.21-0.44)。
- 44%的HER2-zero原发肿瘤在活检时HER2评分升高,22%的HER2-low原发肿瘤转为HER2-IHC 0。
- 激素受体阳性亚组(K=0.32,95%CI 0.19-0.45)和三阴性亚组(K=0.18,95%CI -0.09-0.46)结果与主要分析一致。
- HER2-low与HER2-zero原发肿瘤间无生存结局差异。
关键数值与推荐
- HER2-zero定义为IHC 0,HER2-low定义为IHC 1+或2+/ISH阴性。
- 总体人群原发肿瘤与配对活检间HER2表达不一致K=0.33(95%CI 0.21-0.44)。
- 激素受体阳性亚组K=0.32(95%CI 0.19-0.45),三阴性亚组K=0.18(95%CI -0.09-0.46)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this biomarker during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications. METHODS: We reviewed data of patients with HER2-negative BC according to the latest ASCO/CAP guidelines referred between January 2014 and December 2020. We grouped patients based on the immunohistochemistry (IHC) expression of HER2, HER2-zero (IHC 0) and HER2-low subgroup (IHC 1+ or 2+/ISH-negative) and evaluated the evolution of HER2 expression between the primary tumour and the first biopsy collected in the advanced setting. Disease-free survival, overall survival and progression-free survival were compared between patients with HER2-zero and HER2-low expression on the primary tumour. RESULTS: 232 patients were included in the analysis. Among the overall population, there was a relevant discordance in HER2 expression between the primary tumour and the matched biopsy (K = 0.33, 95%CI 0.21-0.44): 44% of the HER2-zero primary tumour showed an increased HER2 score on biopsy, and 22% of the HER2-low primary tumours turned into HER2-IHC 0. The findings in the sub-populations of hormone-receptors positive (K = 0.32, 95%CI 0.19-0.45) and triple-negative tumours (K = 0.18, 95%CI -0.09-0.46) were consistent with the primary analysis. No difference in survival outcomes was observed between HER2-low and HER2-zero primary tumours. CONCLUSIONS: HER2-low expression is dynamic in BC and may be enriched in the advanced-stage setting. No prognostic significance was demonstrated for HER2-low expression.
引用
- Tarantino P, Gandini S, Nicolò E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer. 2022. PMID: 35032815. doi:10.1016/j.ejca.2021.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。